Blinded in Silico Drug Trial Reveals the Minimum Set of Ion Channels for Torsades De Pointes Risk Assessment

Frontiers in Pharmacology - Switzerland
doi 10.3389/fphar.2019.01643
Full Text
Abstract

Available in full text

Categories
Pharmacology
Date
Authors
Publisher

Frontiers Media SA

Related search

Predicting Drug-Induced QT Prolongation and Torsades De Pointes

Journal of Physiology
PhysiologySports Science
2016English

Additional Causes of Torsades De Pointes

Mayo Clinic Proceedings
Medicine
1995English

Allelic Variants in Long-Qt Disease Genes in Patients With Drug-Associated Torsades De Pointes

Circulation
Cardiovascular MedicinePhysiologyCardiology
2002English

QT Interval Prolongation and Torsades De Pointes With Oxaliplatin

Therapeutic Advances in Drug Safety
Pharmacology
2016English

A History of Drug-Induced Torsades De Pointes Is Associated With T-Wave Morphological Abnormalities

Clinical Pharmacology and Therapeutics
Pharmacology
2017English

Novel Rare Variants in Congenital Cardiac Arrhythmia Genes Are Frequent in Drug-Induced Torsades De Pointes

Pharmacogenomics Journal
Molecular MedicineGeneticsPharmacology
2012English

Atrio-Ventricular Block-Induced Torsades De Pointes: An Update

2011English

Genome Wide Analysis of Drug-Induced Torsades De Pointes: Lack of Common Variants With Large Effect Sizes

PLoS ONE
Multidisciplinary
2013English

A Case of Torsades De Pointes Caused by Overdose of Paroxetine

Journal of the Japanese Society of Intensive Care Medicine
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy